Eliza Ward: Hey — good to be here. We have something today.
Brian Reed: Yeah, I've been sitting with this since the news dropped. Still processing.
Eliza Ward: The FDA approved daraxonrasib — brand name Rasonque, made by Revolution Medicines — August 26th. Yesterday, basically. First targeted precision pill for pancreatic cancer.
Brian Reed: First one. Ever.
Eliza Ward: First one. And the trial numbers — okay, the RASolute 302 Phase 3 trial. Median overall survival: 13.2 months on daraxonrasib, 6.7 months on chemo. Hazard ratio of 0.40.
Brian Reed: Which means — wait, let me make sure I have this — a 60% reduction in risk of death.
Eliza Ward: 60%. Right. And I want to sit with that number because it sounds enormous, and it is real, but — 13.2 months versus 6.7 is what that looks like in actual time. Those are not cure numbers. They're extension numbers.
Brian Reed: Brian Wolpin at Dana-Farber led this trial — and he noted there's basically no precedent for an HR of 0.40 in second-line pancreatic cancer. That's the part that made me stop. Not the framing — the actual number.
Eliza Ward: And that number is real — but I want to push on what made it possible, because KRAS was considered completely undruggable for decades. Not hard. Undruggable.
Brian Reed: Right, and the reason is actually — okay, think of KRAS as a light switch that's stuck in the on position. Cancer on, full blast. But there's no handle. No groove, no pocket on the protein where a drug molecule can grab and flip it off. That's what undruggable meant.
Eliza Ward: So sotorasib and adagrasib — they found a handle?
Brian Reed: They found a tiny lever on one very specific version of that stuck switch — the G12C mutation. Amgen's sotorasib, Mirati's adagrasib. But G12C in pancreatic cancer? That's fewer than 2% of KRAS mutations. So the lever existed, it just — it wasn't where most pancreatic cancer patients needed it.
Eliza Ward: Which means lung cancer got the benefit first, and pancreatic cancer patients were basically watching from outside.
Brian Reed: And what daraxonrasib does differently — it's a multi-selective RAS-ON inhibitor, meaning it covers the mutation subtypes that actually drive pancreatic cancer. Not just G12C. That's the real unlock. Memorial Sloan Kettering called it the first therapy to directly attack the genetic cause of the most common form of pancreatic cancer. Not a broader claim. That specific one.
Eliza Ward: Wait — first to directly attack the genetic cause. Not first KRAS drug. First to hit the mutation that's actually there in most patients.
Brian Reed: That's the distinction that I think gets lost. And the Phase 1/2 data — New England Journal of Medicine published it May 6th, 2026. The FDA had already granted Breakthrough Designation back in June 2025. So the review process was running alongside the science going public, almost in real time.
Eliza Ward: June 2025 designation, May 2026 NEJM publication, August 26th full approval. That's fast — and I mean warranted given the data, but it means the questions about real-world prescribing are still very much open.
Brian Reed: But the prescribing questions — hang on, before we get there — the framing is already out. 'Nearly doubled survival.' That's in the press releases, that's in PanCAN's patient explainer. And I want to know if that's actually misleading.
Eliza Ward: It's technically true and I think it does real harm.
Brian Reed: Wait — harm is a strong word. The baseline sat at 6 to 7 months for decades. Decades. Moving that to 13.2 — isn't that the definition of significant?
Eliza Ward: It is significant. The oncologist commentary — @nlindenberg, 22,000 views — called it no precedent for HR 0.40 in second-line pancreatic cancer. That's a real oncologist saying the number is historically extraordinary. I'm not disputing the number.
Brian Reed: So what's the harm, exactly?
Eliza Ward: Okay — picture a patient. Tuesday afternoon, oncology clinic. They hear 'nearly doubled.' That word, doubled, it maps onto something. Recovery. Time. And what the data actually shows is that half the patients on daraxonrasib were still dead before 14 months. That same commentary that praised the hazard ratio noted it. 500 patients, 59 sites, six countries — that's a rigorous trial. And 50% of people in the treatment arm didn't see month 14.
Brian Reed: So both things are true simultaneously — no precedent historically, and the disease is still killing most patients within roughly a year.
Eliza Ward: Both things are true. And 'nearly doubled' erases the second one. The drug extends a median survival that remains deeply short. It does not approach a cure — and the framing doesn't say that. PanCAN's explainer is written for patients. That's the audience that needs the honest version most.
Brian Reed: And the part that gets even messier — what happens when you layer the no-companion-diagnostic approval on top of this, and these first-line trials Revolution Medicines announced. That's where I think the real gap between the headline and the clinic opens up.
Eliza Ward: That gap is — okay, this is the thing I keep turning over. The FDA approved daraxonrasib without requiring a companion diagnostic. No test needed to prescribe it. Which sounds like a win for access. But think about what actually happens in a clinic that doesn't have rapid sequencing. An oncologist writes the prescription, sends it to the insurer, and the insurer says — wait, where's the mutation confirmation?
Brian Reed: And we don't have coverage guidance yet. Pricing isn't public. Insurance hasn't weighed in.
Eliza Ward: Right — so the approval says no test required, but the reimbursement decision might quietly require one anyway. Those are two completely separate tracks.
Brian Reed: And the wildtype patients — I mean, hang on, because this is the part that actually stops me. More than 91% of RASolute 302 enrollees had confirmed KRAS mutations. That leaves fewer than 50 patients in a 500-person trial without one. We have no idea if daraxonrasib worked in them at all. And it's approved for them too.
Eliza Ward: Fewer than 50. Out of 500.
Brian Reed: So an oncologist — let's say she's got a patient who hasn't been sequenced, small community hospital in a place without rapid molecular testing. The FDA says prescribe it. But does she? Actually, does she just order the sequencing anyway, even though she's not required to, because she wants to know whether this drug has any evidence base for this specific patient?
Eliza Ward: That's — yeah, that's the testing paradox. The approval removes the mandate but it doesn't remove the clinical logic. Most oncologists will test because the data behind the wildtype approval is basically a rounding error.
Brian Reed: And then Revolution Medicines has announced two more Phase 3 trials — first-line metastatic PDAC, adjuvant in resectable PDAC. Announced. Not initiated. No timelines. So the signal to watch isn't those trials themselves, it's whether coverage decisions and sequencing practice actually catch up to what the FDA already said yes to.
Eliza Ward: The Expanded Access Authorization went through May 1st, 2026 — before full approval. So some patients were already getting it under that. What insurers did with those claims is probably the first real data point on how reimbursement is going to land. That's the number I want to see.
Brian Reed: And we may never see that data cleanly. Insurance claims aren't public. So — the confirmed thing is Revolution Medicines holds the approval, the RASolute 302 data are solid, daraxonrasib is real and it works. That's not in question. The three things we genuinely don't know: what happened in the wildtype patients, what coverage actually looks like when a claim hits a desk, and whether the first-line trials — whenever they start — actually widen the survival window past 13 months.
Eliza Ward: That's the shape of it. And I'd add — the confirmed piece is actually historic. KRAS undruggable for decades. Sotorasib, adagrasib, they got a foothold in lung cancer on the G12C subtype. But pancreatic cancer, the mutation profile that actually kills most people — that was still locked. Daraxonrasib is the first targeted precision pill for that disease. That part is settled.
Brian Reed: First one. For a disease that's been essentially untouched by precision medicine.
Eliza Ward: Right. And we've solved — I mean, Revolution Medicines cracked something real. But the lethal problem? 13.2 months median. That's the current ceiling. What would actually settle the open part is coverage guidance from major insurers, and eventually, first-line trial data. Not announcements — actual results. Until then we're guessing at whether the access works in practice.
Brian Reed: Undruggable problem — solved. Lethal problem — still open. That's where we are.
